BiotechTube

Apatinib

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nasopharyngeal Neoplasms

Conditions

Nasopharyngeal Neoplasms

Trial Timeline

Apr 1, 2017 → Apr 1, 2020

NCT ID
NCT03180476

About Apatinib

Apatinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Nasopharyngeal Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT03180476. Target conditions include Nasopharyngeal Neoplasms.

What happened to similar drugs?

0 of 13 similar drugs in Nasopharyngeal Neoplasms were approved

Approved (0) Terminated (0) Active (13)
🔄CisplatinSun PharmaceuticalPhase 3
🔄Cisplatin 1 + Cisplatin 2 + Docetaxel + XelodaSun PharmaceuticalPhase 3
🔄5-fu + Lobaplatin + Placebo + leucogenSun PharmaceuticalPhase 3
🔄CapecitabineSun PharmaceuticalPhase 3
🔄Nedaplatin + CisplatinSun PharmaceuticalPhase 3
🔄PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
🔄QL1706 + Gemcitabine + CisplatinSun PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT05029453ApprovedUNKNOWN
NCT03709953Phase 2UNKNOWN
NCT03457467Phase 2UNKNOWN
NCT03521219Phase 2UNKNOWN
NCT03390062Phase 2UNKNOWN
NCT03403452Phase 2UNKNOWN
NCT03383237Phase 2UNKNOWN
NCT03376737Phase 2UNKNOWN
NCT03251443Phase 2Completed
NCT03190616Phase 2Completed
NCT03163381Phase 2UNKNOWN
NCT03180476Phase 2Completed
NCT03144856Phase 2UNKNOWN
NCT03170310Phase 2UNKNOWN
NCT02764268Pre-clinicalCompleted
NCT02727309Phase 1/2UNKNOWN
NCT02509806Phase 2/3UNKNOWN
NCT02510469Phase 2/3UNKNOWN
NCT01653561Phase 2Completed
NCT01192971Phase 2Completed

Competing Products

20 competing products in Nasopharyngeal Neoplasms

See all competitors
ProductCompanyStageHype Score
Nanatinostat + Valganciclovir + PembrolizumabViracta TherapeuticsPhase 1
11
Cisplatin 2 + Docetaxel + Cisplatin 1Sun PharmaceuticalPhase 2
31
CisplatinSun PharmaceuticalPhase 3
36
Cisplatin 1 + Cisplatin 2 + Docetaxel + XelodaSun PharmaceuticalPhase 3
36
5-fu + Lobaplatin + Placebo + leucogenSun PharmaceuticalPhase 3
47
CapecitabineSun PharmaceuticalPhase 3
36
Amifostine every-other-day regimen + Amifostine everyday regimenSun PharmaceuticalPhase 2
31
Nedaplatin + CisplatinSun PharmaceuticalPhase 3
40
PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
47
QL1706 + Gemcitabine + CisplatinSun PharmaceuticalPhase 3
47
The combination treatment of anlotinib, penpulimab and capecitabine.Sun PharmaceuticalPhase 2
39
docetaxel, nedaplatin, and capecitabine + nedaplatin + docetaxel, cisplatin, and fluorouracil + cisplatin + docetaxel, cisplatin, and capecitabine + docetaxel, nedaplatin, and fluorouracilSun PharmaceuticalPhase 3
47
Pemetrexed (Alimta)Eli LillyPhase 2
35
Camrelizumab + Placebos + Gemcitabine + CisplatinJiangsu Hengrui MedicinePhase 3
36
Famitinib + CisplatinJiangsu Hengrui MedicinePhase 1
29
SHR-1210 + Gemcitabine + cis-platinumJiangsu Hengrui MedicinePhase 1
29
SHR-1701 + Gemcitabine + Cisplatin + Albumin PaclitaxelJiangsu Hengrui MedicinePhase 1
25
FamitinibJiangsu Hengrui MedicinePhase 2
35
SHR-1210Jiangsu Hengrui MedicinePhase 2
35
SHR-1701 + FamitinibJiangsu Hengrui MedicinePhase 1/2
28